Quantcast

Latest PD-L1 Stories

2015-04-19 08:21:14

KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab,

2015-04-16 04:21:54

OXFORD, England, April 16, 2015 /PRNewswire/ -- Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases,

2015-03-29 08:20:59

Research Provides Potential Implications for Immunotherapy in Treatment of Gynecologic Cancers IRVING, Texas, March 29, 2015 /PRNewswire/ -- Caris Life Sciences® today announced the

2015-03-26 08:33:21

CALGARY, March 26, 2015 /PRNewswire/ - Oncolytics Biotech(®) Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr.

2015-02-27 16:26:19

SUNNYVALE, Calif., Feb. 27, 2015 /PRNewswire/ -- Pharmacyclics, Inc.

2014-12-12 23:01:24

Studies Find Potentially Predictive Biomarkers May Lead to Better Patient Outcomes, Bladder Cancer Treatment Options Extend Beyond Chemotherapy Milwaukee, WI

2014-12-11 08:28:27

Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,

2014-11-12 08:31:49

Results Published in Cancer Epidemiology, Biomarkers & Prevention Demonstrate Utility of Caris Molecular Intelligence(TM) in Exploring Expression of Targetable Immune Proteins IRVING,

2014-08-25 12:27:19

Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications PLEASANTON, Calif., Aug.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related